LDLR and familial hypercholesterolemia: In addition, in hepatocarcinoma, the increased levels of LDLR have been associated with the downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), a new pivotal pharmacological target for controlling hypercholesterolemia [33].